Immuneering Corp logo

Immuneering Corp(IMRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.71
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IMRX

11/13/2026: IMRX (1-star) is currently NOT-A-BUY. Pass it for now.

Immuneering Corp is a clinical-stage biopharmaceutical stock focused on discovering and developing deep cyclic inhibitor medicines for advanced oncology indications. Its primary strengths lie in its proprietary discovery platform and advancing lead candidate atebimetinib into pivotal late-stage trials for pancreatic and lung cancers. The core investment opportunity rests on potential clinical breakthroughs and combination therapy synergies in high-unmet-need cancer markets. Key risks include an absence of product revenue, ongoing operating losses, and binary clinical trial outcomes. The stock suits risk-tolerant growth investors who should closely monitor upcoming clinical data readouts and regulatory updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveSuits aggressive growth mandates seeking high-risk, high-reward clinical trial catalysts in oncology.
Momentum investorStrong fit while signal remains positiveTreat Momentum fit as conditional on a positive Upturn signal and sharp clinical data-driven trading volume surges.
Value investorWeak fitLacks traditional earnings, book value safety margins, or cash flows required for conventional value criteria.
Dividend investorWeak fitDoes not pay dividends, rendering it completely unsuitable for income-focused strategies.
Low-risk investorWeak fitExhibits high clinical binary risk and share price volatility characteristic of early-stage biotechs.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences sharp price swings reacting to clinical trial updates and biotech market sentiment.
Valuation riskHighValuation relies entirely on speculative future drug approvals rather than current fundamental earnings.
Competition risk (targeted oncology and MAPK pathway inhibition)HighNumerous well-funded competitors are simultaneously developing alternative therapies for RAS/MAPK driven cancers.
Business qualityMediumFeatures an innovative proprietary discovery platform, though offset by early-stage operational pre-revenue status.
Dividend incomeLow / noneThe company provides zero dividend yield.
Execution riskHighSuccessful execution relies heavily on complex clinical trial outcomes and regulatory navigation.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 240.27M USD
Price to earnings Ratio -
1Y Target Price 17
Price to earnings Ratio -
1Y Target Price 17
Volume (30-day avg) 782.9K shares
Beta 0.46
52 Weeks Range 3.35 - 8.48
Updated Date 11/15/2026
52 Weeks Range 3.35 - 8.48
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.92

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 44.06%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IMRX receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
IMRX has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+8.2%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
IMRX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is IMRX's strongest growth driver at +17.4% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 58.0% and approximately 76.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.24% supports management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 14.98%
BlackRock Inc 6.75%
Sanofi 4.18%
Vanguard Capital Management, LLC 3.53%
T. Rowe Price Associates, Inc. 2.99%

Unit Economics (Per $1K Revenue)

★★★★★
IMRX generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
IMRX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Research and DevelopmentFuture commercial sales or licensing milestones derived from oncology drug candidates such as atebimetinib and envometinib.The company currently generates no product revenue and relies on external financing while advancing its drug pipeline.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 98.40M
Price to Sales(TTM) 563.62
Enterprise Value 98.40M
Price to Sales(TTM) 563.62
Enterprise Value to Revenue 191913.54
Enterprise Value to EBITDA -1.53
Shares Outstanding 64.76M
Shares Floating 49.28M
Shares Outstanding 64.76M
Shares Floating 49.28M
Percent Insiders 14.24
Percent Institutions 58.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.